Insight that enriches. Precision that empowers.
We are advancing a novel class of targeted therapies that directly address the genetic alterations associated with selected tumors.
Our Science
Our powerful synthetic lethality-based approach to the development of new precision oncology therapeutics has multiple potential benefits.
Our Pipeline
We are leveraging our proprietary SNIPRx® platform to discover, validate and build a robust pipeline of synthetic lethality-based therapeutics.
Our Clinical Trials
We are developing a portfolio of product candidates based on targets identified using our SNIPRx platform to treat cancers with a high unmet medical need.